Key result
Mid-life 10-year ASCVD risk was predictive of late-life neurodegeneration (HR 6.98; 95% CI 2.44-19.95; p<0.05) and white matter hyperintensities, but not amyloid or tau.
Why the study?
Mid-life ASCVD risk factors are linked to cognitive decline and dementia, but their role in Alzheimer's disease pathology remains elusive.
Is mid-life 10-year ASCVD risk associated with late-life biomarkers of Alzheimer's disease, neurodegeneration, and white matter hyperintensities?
Cohort
Is mid-life 10-year ASCVD risk associated with late-life biomarkers of Alzheimer's disease, neurodegeneration, and white matter hyperintensities?
Hazard Ratio: 6.98 (95% CI 2.44–19.95)
p-value: p=< 0.05
Mid-life 10-year ASCVD risk predicts late-life neurodegeneration and white matter hyperintensities, but not Alzheimer's-specific amyloid or tau deposition.
Cautions against practice change from associations alone; leaves open whether mid-life ASCVD risk modification affects AD pathology.
Background: Atherosclerotic cardiovascular disease (ASCVD) risk factors in mid-life are associated with cognitive decline and late-life dementia. However, the role of these risk factors in Alzheimer's disease (AD) pathology remains elusive. Objective: We investigated the association of mid-life 10-year ASCVD risk with late-life amyloid, tau, neurodegeneration [AT(N)] measures and white matter hyperintensities (WMHs). Methods: Participants enrolled in the Heart Strategies Concentrating on Risk Evaluation (Heart SCORE) study between 2003-2005 (mid-life) and underwent brain MRI and PET scans in 2018-2022 (age >65 years, late-life) to detect and quantify amyloid (A, PiB-PET) and tau (T, Flortaucipir (FTP) PET) deposition, cortical thickness (N) and WMHs. Mid-life ASCVD risk was categorized as; borderline (5%-7.4%), intermediate (7.5%-<15%), or high (≥15%). Association of mid-life ASCVD risk HR (95% CI) was assessed using logistic and linear regressions with A, T, or N and chi square beta coefficients for WMH in late life. Results: 6.98 [2.44-19.95]; p < 0.05) driven primarily by self-identified Black race and age, while none with A and T. ASCVD risk score was also associated with WMHs ((β=0.42 ± 0.22; p = 0.05). Conclusions: In this asymptomatic, diverse cohort, 10-year ASCVD risk was predictive of late-life neurodegeneration and WMHs but not amyloid or tau. Further mechanistic studies can elucidate whether midlife ASCVD risk factors associated neurodegeneration initiates brain vulnerability leading to AD in late life.
No takes yet. Share an insight, caveat, or question.
Saeed et al. (2025) conducted a cohort in Mid-life cardiovascular risk. Mid-life 10-year ASCVD risk was evaluated on Late-life neurodegeneration (HR 6.98, 95% CI 2.44-19.95, p=< 0.05). Mid-life 10-year ASCVD risk was predictive of late-life neurodegeneration (HR 6.98; 95% CI 2.44-19.95; p<0.05) and white matter hyperintensities, but not amyloid or tau.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: